Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
1.
Biochim Biophys Acta Rev Cancer ; 1879(1): 188995, 2024 01.
Article in English | MEDLINE | ID: mdl-37806640

ABSTRACT

One in five women with breast cancer will relapse despite ideal treatment. Body weight and physical activity are strongly associated with recurrence risk, thus lifestyle modification is an attractive strategy to improve prognosis. Trials of dietary modification in breast cancer are promising but the role of specific diets is unclear, as is whether high-quality diet without weight loss can impact prognosis. Advanced glycation end-products (AGEs) are compounds produced in the body during sugar metabolism. Exogenous AGEs, such as those found in food, combined with endogenous AGEs, make up the total body AGE load. AGEs deposit in tissues over time impacting cell signaling pathways and altering protein functions. AGEs can be measured or estimated in the diet and measured in blood through their metabolites. Studies demonstrate an association between AGEs and breast cancer risk and prognosis. Here, we review the clinical data on dietary and serum AGEs in breast cancer.


Subject(s)
Breast Neoplasms , Glycation End Products, Advanced , Humans , Female , Glycation End Products, Advanced/metabolism , Glycation End Products, Advanced/therapeutic use , Breast Neoplasms/drug therapy , Maillard Reaction , Diet
2.
Stem Cells Transl Med ; 13(3): 243-254, 2024 Mar 15.
Article in English | MEDLINE | ID: mdl-38134964

ABSTRACT

Increased bone fragility and poor bone healing are common and serious complications of diabetes, especially in elderly patients. Long-term hyperglycemia often leads to serious infection and nonunion. Diabetes brings changes to bone microenvironment, including imbalanced immunity, disorder of macrophage polarization, deterioration of microvascular system, excessive advanced glycation end products, reactive oxygen species (ROS), local high levels of glucose, and great tendency to infection. The main traditional managements of diabetic bone involve oral medication and systematic drug administration, which exhibit limited therapeutic efficacy and accompanied side effects. Materials-based strategies have recently been potential alternatives for the treatment of diabetic bone diseases. In this review, we highlight the main material-based strategies for diabetic bone repair deficiency, including regulation of macrophages, elimination of excessive ROS, and resistance to bacterial infection. We also describe the future therapeutic designing approaches for smart biomaterials for diabetic bone regeneration, which would provide new ideas to protect bone health in patients with diabetes.


Subject(s)
Diabetes Mellitus , Hyperglycemia , Humans , Aged , Reactive Oxygen Species , Hyperglycemia/drug therapy , Glycation End Products, Advanced/therapeutic use , Bone Regeneration
3.
Eur J Gastroenterol Hepatol ; 35(7): 777-781, 2023 07 01.
Article in English | MEDLINE | ID: mdl-37161982

ABSTRACT

OBJECTIVE: This study aimed to investigate the clinical effect of probiotics combined with lactulose for minimal hepatic encephalopathy (MHE) treatment. METHODS: A total of 88 patients with MHE were randomly divided into the control ( n  = 44) and combined groups ( n  = 44). The control group was treated with lactulose, while the combined group was treated with probiotics and lactulose. Serum ammonia, liver function [alanine aminotransferase (ALT) and aspartate transaminase (AST)], intestinal mucosal barrier markers [fatty acid-binding protein 2 (FABP2) and advanced glycation end-products (AGEs)] and number connection test A (NCT-A) and digit symbol test (DST) scores were tested and compared between the two groups. RESULTS: The post-treatment in the control and combined groups shows decreased serum ammonia levels, ALT and AST levels, FABP2 and AGEs levels and NCT-A score and increased DST score compared with pre-treatment, with a significant difference ( P  < 0.05). Post-treatment, the serum ammonia level, ALT and AST levels, FABP2 and AGEs levels, NCT-A score decreased and DST score increased in the combined group compared with the control group, with a significant difference ( P  < 0.05). CONCLUSION: Probiotics can promote lactulose in MHE treatment.


Subject(s)
Hepatic Encephalopathy , Probiotics , Humans , Lactulose/therapeutic use , Hepatic Encephalopathy/drug therapy , Ammonia , Probiotics/therapeutic use , Glycation End Products, Advanced/therapeutic use , Liver Cirrhosis/drug therapy
4.
Maturitas ; 172: 32-38, 2023 Jun.
Article in English | MEDLINE | ID: mdl-37084590

ABSTRACT

OBJECTIVE: Postmenopausal hot flashes are associated with an increased risk of cardiovascular disease and diabetes. Because dietary advanced glycation end-products (AGEs) may act as endocrine disruptors, this study examined the potential association of modifications to the intake of dietary AGEs with the frequency and severity of postmenopausal hot flashes. METHODS: Postmenopausal women (n = 84) reporting ≥2 moderate-to-severe hot flashes daily were randomly assigned to either the intervention group or the control group. The former were asked to follow a low-fat, vegan diet, including cooked soybeans (1/2 cup [86 g]/day) for 12 weeks, and the latter continued their usual diets for 12 weeks. Frequency and severity of hot flashes were recorded with a mobile application. Three-day diet records were analyzed using the Nutrition Data System for Research software and dietary AGEs were estimated, using a database. Seventy-one participants completed the whole study and 63 provided complete hot flash and dietary data for the AGEs analysis (n = 31 in the intervention and n = 24 in the control group). Pearson correlations were used to assess the association between changes in hot flashes and dietary AGEs. RESULTS: Dietary AGEs decreased in the intervention group by 73 %, that is by 5509 ku/day on average (95 % -7009 to -4009; p < 0.001), compared with the control group (+458; 95 % CI -835 to +1751; p = 0.47; treatment effect -5968 ku/day [95 % CI -7945 to -3991]; Gxt, p < 0.001). Severe hot flashes decreased by 92 % (p < 0.001) and moderate-to-severe hot flashes decreased by 88 % in the intervention group (p < 0.001). Changes in dietary AGEs correlated with changes in severe (r = +0.39; p = 0.002) and moderate hot flashes (r = +0.34; p = 0.009) and remained significant after adjustment for changes in energy intake (r = +0.45; p < 0.001; and r = +0.37; p = 0.004, respectively) and changes in body mass index (r = +0.37; p = 0.004; and r = +0.27; p = 0.04, respectively). The reduction in dietary AGEs required to achieve a predicted reduction in hot flashes by 1/day was 6933 ku/day for severe and 4366 ku/day for moderate-to-severe hot flashes. CONCLUSIONS: The reduction in dietary AGEs with a low-fat plant-based diet was associated with a significant reduction in the frequency of severe and moderate-to-severe postmenopausal hot flashes, independent of changes in energy intake and weight loss. Plant-based diets could be used not only to alleviate vasomotor symptoms in postmenopausal women, but also to reduce other health risks associated with AGEs. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04587154.


Subject(s)
Hot Flashes , Postmenopause , Female , Humans , Hot Flashes/therapy , Maillard Reaction , Energy Intake , Glycation End Products, Advanced/therapeutic use , Menopause
5.
Environ Sci Pollut Res Int ; 30(12): 33942-33948, 2023 Mar.
Article in English | MEDLINE | ID: mdl-36496522

ABSTRACT

The protein glycation due to high blood glucose mediate release of inflammatory intermediate contributes in the development of diabetic nephropathy. Ferulic acid (FA) is a phenolic compound distributed in different foods as whole grains. Inhibitors of DPP4 improve GLP-1-mediated insulin secretion and inhibit liver gluconeogenesis. This study investigated the impact of FA as anti-inflammatory, antioxidant and antiglycation against streptozotocin-induced diabetic nephropathy in rats. This study was carried out on total ninety male rats allocated into six (each 15 rats); group I (control). All other animals (groups II-VI) were receiving 65 mg/kg STZ for induction of diabetes. Rats in group II (untreated diabetic). Rats in groups III-V were treated with FA (10, 20, 30 mg/kg bw) respectively, i.p. for 8 weeks. Group VI received 10 units insulin daily, sc. Fasting blood samples were subjected for assay of glycated hemoglobin (HA1c), serum MDA, aldose reductase, total antioxidant, DPP4 while kidney tissue subjected for assay of malondialdehyde (MDA), reduced glutathione (GSH), catalase (CAT), superoxide dismutase (SOD), tumor necrosis factor-α (TNF-α), IL-1ß and AGEs. Data obtained showed that, FA showed antioxidant activity by reducing MDA and enhancement antioxidant activity compared with untreated rats (p < 0.001) with dose dependence. In addition, FA reduced the activities of aldose reductase, DPP4 (p < 0.001), decreased IL-6, TNF-α and AGEs versus untreated rats (p < 0.001). Histological investigation revealed an improvement in the nephron structure in diabetic rat treated with FA versus untreated group. It was concluded that, FA possesses a potent antioxidant and anti-inflammatory and DPP4 inhibitor. For that, it was considered as a protective agent against the risk of diabetic nephropathy and can be used as alternative or complementary supplement.


Subject(s)
Diabetes Mellitus, Experimental , Diabetic Nephropathies , Rats , Male , Animals , Antioxidants/metabolism , Diabetic Nephropathies/drug therapy , Diabetic Nephropathies/metabolism , Diabetic Nephropathies/pathology , Aldehyde Reductase/metabolism , Streptozocin/pharmacology , Streptozocin/therapeutic use , Oxidative Stress , Diabetes Mellitus, Experimental/drug therapy , Dipeptidyl Peptidase 4/metabolism , Tumor Necrosis Factor-alpha/metabolism , Anti-Inflammatory Agents/pharmacology , Glycation End Products, Advanced/metabolism , Glycation End Products, Advanced/pharmacology , Glycation End Products, Advanced/therapeutic use
6.
J Food Biochem ; 46(12): e14467, 2022 12.
Article in English | MEDLINE | ID: mdl-36219760

ABSTRACT

This study evaluates the synergistic effect of garlic and Citrullus colocynthis on diabetic reproductive damage by suppressing the AGEs/RAGE/Nox-4 signaling pathway. Thirty-five male Wistar rats were divided into five groups (n = 7/group): Control, Diabetic, Diabetic+G (Garlic, 1 mL/100 g b.w), Diabetic+C (C. colocynthis, 10 mg/kg b.w) and Diabetic+GC (Garlic, 1 mL/100 g b.w and C. colocynthis, 10 mg/kg b.w) groups. At the end of the experimental period (30 days), in diabetic rats, glucose increased, and body & testis weight, luteinizing hormone (LH) and testosterone levels, and sperm count decreased significantly and histopathological injuries were observed. In addition, they have increased testicular apoptosis and oxidative stress. Also, the mechanism based on advanced glycation end products (AGEs)/receptors for advanced glycation end products (RAGE)/NADPH oxidase-4 (Nox-4) was activated in diabetic rats. Separate consumption of garlic and C. colocynthis in Diabetic+G and Diabetic+C groups alleviated the negative adverse effect of diabetes to some extent, but when they were used in the combination form (Diabetic+GC) improvement was profound. Testis histopathology, increased body and testis weight, and enhanced capacity in protecting diabetic reproductive injury was seen. Decreases in testosterone and LH concentration and sperm count in diabetic rats were also reversed by combined administration of garlic and C. colocynthis. It regulated oxidative stress markers, meanwhile reducing caspase-3 immunoexpression. In addition, overexpression of RAGE, Nox-4 and nuclear transcription factor-κB (NF-κB) was inhibited by the combination of garlic and C. colocynthis. PRACTICAL APPLICATIONS: Diabetes mellitus is wide spread all around the world with variety of complications in body including reproductive system in which patients suffer from physical and psychological aspects. Despite many efforts in providing agents for controlling diabetes and its complications, economic conditions of some countries make it difficult for people to provide costly medicine and as a result, they have to bear the complications until they pass away. However, traditional medicine is still finding its way, especially in poor countries with emphasis on medicinal plants. There have been many studies on plants to alleviate diabetes or its side effects. But, using one plant for long term, may be not so effective. Here, we attempted to find whether two plants from two different species can show more efficacy than each one alone. We noticed garlic and Citrullus colocynthis despite having beneficial effects when used alone, they could show synergistic effects in combination.


Subject(s)
Citrullus colocynthis , Diabetes Mellitus, Experimental , Garlic , Rats , Male , Animals , Citrullus colocynthis/metabolism , Garlic/metabolism , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Experimental/complications , Rats, Wistar , Seeds/metabolism , Antioxidants/pharmacology , Receptor for Advanced Glycation End Products/metabolism , Receptor for Advanced Glycation End Products/therapeutic use , Testosterone , Glycation End Products, Advanced/metabolism , Glycation End Products, Advanced/therapeutic use
7.
Respir Investig ; 60(4): 531-542, 2022 Jul.
Article in English | MEDLINE | ID: mdl-35504814

ABSTRACT

The receptor for advanced glycation end product (RAGE) is a transmembrane receptor highly expressed in type 1 pneumocytes of healthy lungs. RAGE is considered to play a homeostatic role in the lung, as RAGE knockout mice develop lung fibrosis as they age. In contrast, RAGE can bind numerous ligands, including high-mobility group box 1 (HMGB1). These interactions initiate pro-inflammatory signaling associated with the pathogenesis of lung injury and interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF). ILD is a broad category of diffuse parenchymal lung disease characterized by various extents of lung fibrosis and inflammation, and IPF is a common and progressive ILD of unknown cause. The prognosis of patients with IPF is poor, and acute exacerbation of IPF (AE-IPF) is one of the main causes of death. Recent reports indicate that acute exacerbations can occur in other ILDs (AE-ILD). Notably, ILD is frequently observed in patients with lung cancer, and AE-ILD after surgical procedures or the initiation of chemotherapy for concomitant lung cancer are clinically important due to their association with increased mortality. In this review, we summarize the associations of RAGE/soluble RAGE (sRAGE)/RAGE ligands with the pathogenesis and clinical course of ILD, including IPF and AE-IPF. Additionally, the potential use of sRAGE and RAGE ligands as predictive markers of AE-IPF and cancer treatment-triggered AE-ILD is also discussed.


Subject(s)
Idiopathic Pulmonary Fibrosis , Lung Diseases, Interstitial , Lung Neoplasms , Animals , Disease Progression , Glycation End Products, Advanced/therapeutic use , Ligands , Lung Diseases, Interstitial/pathology , Lung Neoplasms/drug therapy , Mice , Prognosis , Receptor for Advanced Glycation End Products
8.
Cardiovasc Ther ; 2022: 7014680, 2022.
Article in English | MEDLINE | ID: mdl-35414826

ABSTRACT

Introduction: Sphingosine 1 phosphate (S1P) is a product of the sphingosine kinase 1 (SphK1) enzyme. Increased S1P can lead to tissue fibrosis that is also one of the pathways for developing diabetic cardiomyopathy. Advanced glycation end products (AGEs) increase S1P in cells. The study is aimed at using aminoguanidine (AG) as an AGEs blocker drug to prevent diabetic cardiomyopathy. Materials and methods. 210 rats were enrolled in the study. Diabetes mellitus type-2 was induced, and rats were divided into AG treated diabetic and nondiabetic groups. The heart histology was assessed with Masson's trichrome and hematoxylin-eosin staining. Cardiac function was measured with transthoracic echocardiography. S1P level and SphK1 gene expression were measured by western-blot and RT-qPCR, respectively. Results: Results showed that S1P level increases in diabetes, and its augmentation in cardiac tissue with K6PC-5 leads to cardiac fibrosis. 50 and 200 mg/kg of AG prevented cardiac fibrosis, but 100 mg/kg had no significant preventive effect. AG suppressed the SphK1 gene expression and reduced the fibrotic effect of S1P. AG preserved cardiac function by keeping ejection fraction and fractional shortening within the normal range in diabetic rats. Conclusion: AG has a suppressor effect on SphK1 gene expression besides its AGEs blocker role. AG is a potential drug to use in diabetic patients for preventing the development of diabetic cardiomyopathy. Other drugs that have AGEs or S1P blocker effects are a good choice for diabetic cardiomyopathy prevention.


Subject(s)
Diabetes Mellitus, Experimental , Diabetes Mellitus, Type 2 , Diabetic Cardiomyopathies , Animals , Diabetes Mellitus, Experimental/complications , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/drug therapy , Diabetic Cardiomyopathies/etiology , Diabetic Cardiomyopathies/prevention & control , Disease Models, Animal , Fibrosis , Glycation End Products, Advanced/metabolism , Glycation End Products, Advanced/therapeutic use , Rats
9.
Int J Impot Res ; 34(2): 222-228, 2022 Mar.
Article in English | MEDLINE | ID: mdl-33712808

ABSTRACT

To investigate, if advanced glycation end products (AGEs) are involved in erectile dysfunction (ED) and also ALT-711, a cross-link breaker of AGEs, has the therapeutic potential against the development of ED in rats treated with high concentrated AGEs including food. For this purpose, 30 male Harlan Spraque-Dawley rats randomly were divided into three groups; (1) control rats treated with regular diet, (2) rats treated with high-level of AGE specific diet for 6 months, and (3) rats having AGE-diet treated with ALT-711 for the final 3 months of 6 months of AGE-diet period. Erectile response to cavernosal nerve stimulation (CNS), protein expression of neuronal nitric oxide synthase (nNOS) and levels of AGEs, Malondialdehyde (MDA), cyclic guanosine monophosphate (cGMP) were determined in penile tissues. Erectile responses to CNS and penile nNOS and cGMP content were significantly reduced, while AGEs and MDA were elevated in penises of Group-2. Treatment with ALT-711 reversed ED and depletion of both nNOS and cGMP. Additionally, ALT-711 treatment reduced penile tissue AGEs and MDA expression. In present study: rats without any co-morbidity such as diabetes mellitus (DM) and chronic renal failure (CRF) were treated with high-level AGEs containing food. Our results suggest that ALT-711 may be an interesting and promising approach in the treatment of AGEs-related ED.


Subject(s)
Diabetes Mellitus, Experimental , Erectile Dysfunction , Animals , Male , Rats , Diabetes Mellitus, Experimental/metabolism , Diet , Glycation End Products, Advanced/metabolism , Glycation End Products, Advanced/pharmacology , Glycation End Products, Advanced/therapeutic use , Nitric Oxide Synthase Type III/metabolism , Penile Erection , Penis , Rats, Sprague-Dawley , Thiazoles
10.
Adv Skin Wound Care ; 34(11): 1-8, 2021 Nov 01.
Article in English | MEDLINE | ID: mdl-34669666

ABSTRACT

OBJECTIVE: Skin autofluorescence (SAF) has been suggested as a novel and noninvasive technique for assessing tissue accumulation of advanced glycation end products in diabetes and related complications. The aim of this systematic review and meta-analysis was to evaluate the use of SAF in diabetic foot ulcers (DFUs). DATA SOURCES: PubMed/MEDLINE and other digital databases. STUDY SELECTION: The authors included studies comparing the SAF levels in patients with DFU with a non-DFU group to determine its association with DFU risk. DATA EXTRACTION: Collected data included the SAF method and its values in DFU and non-DFU groups, covariates used in adjustment along with the unadjusted and/or multivariate adjusted odds ratios (ORs) for the association of SAF with DFU risk, and other study characteristics. DATA SYNTHESIS: A total of six studies were included in this meta-analysis. Five studies that involved 611 participants were included to compare SAF methods. Compared with the non-DFU group, the DFU group showed a significantly increased level of SAF (standardized mean difference, 0.67; 95% confidence interval [CI], 0.32-1.01; P < .001). The results of meta-analysis of ORs revealed that the increased SAF level was independently associated with increased DFU risk in both unadjusted (OR, 3.16; 95% CI, 2.18-4.57; P < .001) and adjusted models (OR, 3.07; 95% CI, 1.95-4.81; P < .001). CONCLUSIONS: These findings suggest that SAF could be useful as a novel and noninvasive technology to help determine DFU risk. However, further studies establishing its diagnostic and prognostic utilities are needed.


Subject(s)
Diabetic Foot/drug therapy , Glycation End Products, Advanced/pharmacology , Optical Imaging/methods , Skin/diagnostic imaging , Aged , Diabetes Mellitus/physiopathology , Diabetic Foot/diagnostic imaging , Glycation End Products, Advanced/therapeutic use , Humans , Middle Aged , Prognosis , Skin/physiopathology
11.
Oxid Med Cell Longev ; 2021: 8850112, 2021.
Article in English | MEDLINE | ID: mdl-34336115

ABSTRACT

The maintenance of homeostasis is essential for mitigating stress and delaying degenerative diseases such as Alzheimer's disease (AD). AD is generally defined as the abnormal production of ß-amyloid (Aß) and advanced glycation end products (AGEs). The effects of l-theanine on Aß and AGE generation were investigated in this study. Decreased AGEs and Aß 1-42 levels were reflected by increased acetylcholine (ACh) concentration and acetylcholinesterase (AChE) activity inhibition compared to model rats. l-Theanine also inhibited nuclear factor-κB (p65) protein expression by activating sirtuin1 (SIRT1), reducing inflammatory factor expression, and downregulating the mRNA and protein expression of AGE receptors (RAGE). Superoxide dismutase 2 and catalase protein expressions were markedly upregulated by l-theanine, whereas oxidative stress-related injury was alleviated. The expression of peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) was also found to be increased. H&E staining showed that the apoptosis of hippocampal neurons was mitigated by decreased Bax and cleaved-caspase-3 protein expression and the increase of Bcl-2 protein expression. Moreover, l-theanine increased the gene and protein expression of brain-derived neurotrophic factor (BDNF). These findings suggest that the potential preventive effects of l-theanine against AD may be attributed to its regulation of SIRT1 and BDNF proteins and its mitigation of AGEs/RAGE signaling pathways in the brain tissue of AD model rats.


Subject(s)
Brain Damage, Chronic/drug therapy , Brain-Derived Neurotrophic Factor/metabolism , Galactose/metabolism , Glutamates/therapeutic use , Glycation End Products, Advanced/therapeutic use , Sirtuin 1/metabolism , Animals , Glutamates/pharmacology , Glycation End Products, Advanced/pharmacology , Male , Neuroprotective Agents , Rats , Rats, Sprague-Dawley
12.
Food Res Int ; 116: 1229-1238, 2019 02.
Article in English | MEDLINE | ID: mdl-30716910

ABSTRACT

Myrica faya Aiton (fire tree, faya) is an underused species with a diverse flavonoid composition (anthocyanins, flavonols, ellagitannins) which can promote positive effects on human health. M. faya has been reported to possess high antioxidant activities, but its potential in the prevention of type II diabetes has not been evaluated so far. In the present study, eight M. faya samples from different areas of Madeira and Azores archipelagos (Portugal) were collected to determine their phytochemical profile and then tested for their in vitro anti-diabetic and antioxidant activities. The analyzed extracts showed strong inhibitory activities towards α -glucosidase, aldose reductase and glycation of bovine serum albumin (BSA) and moderate effects towards α-amylase and lipase (by comparison with reference compounds). Cyanidin-3-O-glucoside and ellagitannins were the main bioactive agents involved in the anti-diabetic effects of M. faya. Such results may provide important scientific evidence for further utilization of M. faya as dietary or nutraceutical products for the prevention and/or control of hyperglycaemia-associated complications.


Subject(s)
Diabetes Complications/prevention & control , Diabetes Mellitus, Type 2/drug therapy , Glycation End Products, Advanced/therapeutic use , Myrica/chemistry , Obesity/drug therapy , Plant Extracts/pharmacology , Polyphenols/pharmacology , Aldehyde Reductase , Anthocyanins , Anti-Obesity Agents/pharmacology , Antioxidants/analysis , Antioxidants/pharmacology , Azores , Enzyme Inhibitors/pharmacology , Flavonoids/analysis , Glucosides , Humans , Hyperglycemia/drug therapy , Hyperglycemia/prevention & control , Hypoglycemic Agents/pharmacology , Lipase , Phytochemicals/pharmacology , Polyphenols/analysis , Portugal , Serum Albumin, Bovine , alpha-Amylases , alpha-Glucosidases/therapeutic use
13.
Endocrinol. diabetes nutr. (Ed. impr.) ; 65(9): 540-545, nov. 2018.
Article in English | IBECS | ID: ibc-176446

ABSTRACT

There are substantial differences in the onset and severity of diabetes complications that are not fully explained by HbA1c levels and other risk factors. HbA1c is the gold standard for assessing metabolic control, but has limited value to identify patients at risk of developing diabetic complications. The main disadvantage of HbA1c is that it does not provide information about glycemic variability and does not reflect long-term exposure to hyperglycemia. One of the main pathogenetic mechanisms of diabetic complications is the generation and accumulation of advanced glycation end-products (AGEs). Based on its fluorescence properties, AGEs may be measured in tissues such as the skin or lens. These non-invasive measurements of AGE accumulation may be considered as promising biomarkers of late diabetic complications, and our objective is to summarize the available evidence supporting this statement. However, further translational research and prospective clinical trials are needed before these new biomarkers may be incorporated into clinical practice


La determinación de HbA1c es el «estándar de oro» para evaluar el control metabólico de los pacientes con diabetes, pero tiene limitaciones en identificar los pacientes riesgo de desarrollar complicaciones. Los inconvenientes de la HbA1c son que no proporciona información acerca de la variabilidad glucémica y no refleja la exposición a largo plazo a la hiperglucemia. Uno de los mecanismos patogénicos de las complicaciones de la diabetes es la acumulación de productos avanzados de la glicación (AGE). Basándose en sus propiedades fluorescentes, los AGE pueden determinarse en tejidos como la piel o el cristalino. Estas determinaciones no invasivas podrían contemplarse como biomarcadores de las complicaciones de la diabetes, y nuestro objetivo es resumir la evidencia disponible en referencia a ello. Sin embargo, es necesaria una mayor investigación traslacional en este campo, así como estudios prospectivos antes de que estos métodos puedan ser incorporados a la práctica clínica


Subject(s)
Humans , Diabetes Complications/metabolism , Glycation End Products, Advanced/therapeutic use , Biomarkers/analysis , Glycated Hemoglobin/therapeutic use , Glycated Hemoglobin/analysis , Fluorescence
14.
Food Funct ; 9(9): 4888-4896, 2018 Sep 19.
Article in English | MEDLINE | ID: mdl-30167607

ABSTRACT

This work addresses the role of different by-products derived from the industrial extraction of orange juice in a possible anti-inflammatory effect in mice with colitis induced by dextran sulfate sodium (DSS). Fresh orange residue (FOR), dry orange residue (DOR), orange liqueur (OL) and animal feed (AF), as well as commercial citrus pectin (CP), were administered to C57BL/6J mice for 15 days before starting the DSS treatment. Analysis of macroscopic parameters such as the Disease Activity Index (DAI) and the colonic weight/length ratio revealed an anti-inflammatory effect following intake of FOR, AF or CP. Moreover, q-PCR of RNA from colonic tissue indicated measurable changes in the expression of TNF-α, IL-1ß, iNOS, and intercellular adhesion molecules ICAM I, as well as in intestinal barrier proteins such as MUC-3, occludin, and ZO-1. Pectin, phenolic compounds and/or Maillard reaction products formed at initial steps were identified as relevant components exerting the ascribed beneficial effects. Our findings could open up the further application of a variety of orange by-products as food supplements in the potential amelioration of inflammatory bowel diseases.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Biological Products/therapeutic use , Citrus sinensis/chemistry , Colitis, Ulcerative/prevention & control , Dietary Supplements , Disease Models, Animal , Fruit/chemistry , Animals , Anti-Inflammatory Agents, Non-Steroidal/analysis , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Anti-Inflammatory Agents, Non-Steroidal/economics , Biological Products/analysis , Biological Products/chemistry , Biological Products/economics , Colitis, Ulcerative/immunology , Colitis, Ulcerative/metabolism , Colitis, Ulcerative/pathology , Colon/immunology , Colon/metabolism , Colon/pathology , Cytokines/antagonists & inhibitors , Cytokines/genetics , Cytokines/metabolism , Dextran Sulfate , Food-Processing Industry/economics , Fruit/economics , Gene Expression Regulation , Glycation End Products, Advanced/analysis , Glycation End Products, Advanced/economics , Glycation End Products, Advanced/therapeutic use , Industrial Waste/analysis , Industrial Waste/economics , Intestinal Mucosa/immunology , Intestinal Mucosa/metabolism , Intestinal Mucosa/pathology , Male , Mice, Inbred C57BL , Pectins/analysis , Pectins/economics , Pectins/therapeutic use , Phenols/analysis , Phenols/economics , Phenols/therapeutic use , Protective Agents/analysis , Protective Agents/chemistry , Protective Agents/economics , Protective Agents/therapeutic use , Specific Pathogen-Free Organisms
15.
Int Immunopharmacol ; 52: 324-332, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28987931

ABSTRACT

Inflammatory bowel diseases (IBDs) are chronic disorders that are characterized by intestinal epithelial inflammation and injury. Currently, the most employed therapies are antibiotics and anti-inflammatory drugs; however, the side effects limit long-term effectiveness. We evaluated the impact of glucose-lysine Maillard reaction products (Glc-Lys MRPs) on colitis, induced in rats by an administration of 5% dextran sulfate sodium (DSS) in drinking water. Glc-Lys MRPs ameliorate DSS-induced colitis, as determined by a decrease in disease index activity, colon weight/length ratio, nitric oxide levels in serum, recovery of body weight loss, colon length and serum lysozyme levels. Furthermore, Glc-Lys MRPs increase the glutathione content and the activity of glutathione peroxidase, superoxide dismutase and catalase, and inhibit lipid peroxidation and myeloperoxidase activity in colon tissues. In particular, Glc-Lys MRPs suppress the mRNA level of the inflammatory cytokines and nuclear factor-κB in colon tissues. This study suggests the potential of Glc-Lys MRPs in preventing or treating IBDs.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Colitis/drug therapy , Colon/pathology , Epithelial Cells/immunology , Glycation End Products, Advanced/therapeutic use , Inflammatory Bowel Diseases/drug therapy , Intestines/pathology , Animals , Colitis/chemically induced , Colitis/immunology , Cytokines/metabolism , Dextran Sulfate/administration & dosage , Disease Models, Animal , Glucose/chemistry , Glycation End Products, Advanced/chemistry , Humans , Inflammation , Inflammation Mediators/metabolism , Inflammatory Bowel Diseases/immunology , Lipid Peroxidation , Lysine/chemistry , Male , Rats , Rats, Wistar
16.
Dig Dis Sci ; 62(12): 3370-3384, 2017 12.
Article in English | MEDLINE | ID: mdl-28965192

ABSTRACT

BACKGROUND: Diet is suggested to participate in the etiology of inflammatory bowel diseases (IBD). Repeated exposure to Maillard reaction products (MRPs), molecules resulting from reduction reactions between amino acids and sugars during food heating, has been reported to be either potentially detrimental or beneficial to health. AIMS: The aim of this study is to determine the effect of repeated oral ingestion of N ε-carboxymethyllysine (CML), an advanced MRP, on the onset of two models of experimental IBD and on the gut microbiota composition of mice. METHODS: Mice received either saline (control) or N ε-carboxymethyllysine daily for 21 days. For the last week of treatment, each group was split into subgroups, receiving dextran sulfate sodium salt (DSS) or trinitrobenzenesulfonic acid (TNBS) to induce colitis. Intensity of inflammation was quantified, and cecal microbiota characterized by bacterial 16S ribosomal RNA (rRNA) amplicon sequencing. RESULTS: Daily oral administration of N ε-carboxymethyllysine did not induce intestinal inflammation and had limited impact on gut microbiota composition (Bacteroidaceae increase, Lachnospiraceae decrease). DSS and TNBS administration resulted in expected moderate experimental colitis with a shift of Bacteroidetes/Firmicutes ratio and a significant Proteobacteria increase but with distinct profiles: different Proteobacteria taxa for DSS, but mainly Enterobacteriaceae for TNBS. While N ε-carboxymethyllysine exposure failed to prevent the inflammatory response, it allowed maintenance of healthy gut microbiota profiles in mice treated with DSS (but not TNBS). CONCLUSIONS: Repeated oral exposure to CML limits dysbiosis in experimental colitis. IBD patients may modulate their microbiota profile by regulating the level and type of dietary MRP consumption.


Subject(s)
Colitis/microbiology , Dysbiosis/drug therapy , Gastrointestinal Microbiome/drug effects , Glycation End Products, Advanced/therapeutic use , Lysine/analogs & derivatives , Administration, Oral , Animals , Colitis/complications , Disease Models, Animal , Drug Evaluation, Preclinical , Dysbiosis/etiology , Eating/drug effects , Glycation End Products, Advanced/pharmacology , Lysine/pharmacology , Lysine/therapeutic use , Male , Mice, Inbred BALB C , Neutrophil Infiltration/drug effects
17.
Eur J Pharmacol ; 791: 535-543, 2016 Nov 15.
Article in English | MEDLINE | ID: mdl-27393458

ABSTRACT

Heart failure is the consequence of sustained, abnormal neurohormonal and mechanical stress and remains a leading cause of death worldwide. The aim of this work was to identify whether blockade of receptor for advanced glycation end products (RAGE) protected against systolic overload-induced heart failure and investigate the possible underlying mechanism. It was found that RAGE mRNA and protein expression was up-regulated in cardiac tissues from mice subjected to pressure overload by transverse aortic constriction (TAC). Importantly, inhibition of RAGE by treatment with soluble RAGE (sRAGE) or FPS-ZM1 (a high-affinity RAGE-specific inhibitor) for 8 weeks attenuated cardiac remodeling (including cardiac hypertrophy and fibrosis), and dysfunction in mice exposed to TAC. Furthermore, treatment of TAC mice with sRAGE or FPS-ZM1 enhanced phosphorylation of AMPK and reduced phosphorylation of mTOR and protein expression of NFκB p65 in cardiac tissues. In addition, treatment of TAC mice with sRAGE or FPS-ZM1 abated oxidative stress, attenuated endoplasmic reticulum stress, and suppressed inflammation in cardiac tissues. These data demonstrated the benefits of blocking RAGE on the progression of systolic overload-induced heart failure in mice, which was possibly through modulating AMPK/mTOR and NFκB pathways.


Subject(s)
Aorta/physiopathology , Heart Failure/drug therapy , Heart Failure/physiopathology , Pressure/adverse effects , Receptor for Advanced Glycation End Products/antagonists & inhibitors , Systole , Vasoconstriction , Animals , Aorta/drug effects , Benzamides/pharmacology , Benzamides/therapeutic use , Endoplasmic Reticulum Stress/drug effects , Fibrosis , Glycation End Products, Advanced/chemistry , Glycation End Products, Advanced/pharmacology , Glycation End Products, Advanced/therapeutic use , Heart Failure/complications , Heart Failure/pathology , Hypertrophy/complications , Male , Mice , Mice, Inbred C57BL , NF-kappa B/metabolism , Oxidative Stress/drug effects , Signal Transduction/drug effects , Solubility , Systole/drug effects , TOR Serine-Threonine Kinases/metabolism , Vasoconstriction/drug effects
18.
Diabetologia ; 59(10): 2181-92, 2016 10.
Article in English | MEDLINE | ID: mdl-27468708

ABSTRACT

AIMS/HYPOTHESIS: We previously reported that obese individuals with the metabolic syndrome (at risk), compared with obese individuals without the metabolic syndrome (healthy obese), have elevated serum AGEs that strongly correlate with insulin resistance, oxidative stress and inflammation. We hypothesised that a diet low in AGEs (L-AGE) would improve components of the metabolic syndrome in obese individuals, confirming high AGEs as a new risk factor for the metabolic syndrome. METHODS: A randomised 1 year trial was conducted in obese individuals with the metabolic syndrome in two parallel groups: L-AGE diet vs a regular diet, habitually high in AGEs (Reg-AGE). Participants were allocated to each group by randomisation using random permuted blocks. At baseline and at the end of the trial, we obtained anthropometric variables, blood and urine samples, and performed OGTTs and MRI measurements of visceral and subcutaneous abdominal tissue and carotid artery. Only investigators involved in laboratory determinations were blinded to dietary assignment. Effects on insulin resistance (HOMA-IR) were the primary outcome. RESULTS: Sixty-one individuals were randomised to a Reg-AGE diet and 77 to an L-AGE diet; the data of 49 and 51, respectively, were analysed at the study end in 2014. The L-AGE diet markedly improved insulin resistance; modestly decreased body weight; lowered AGEs, oxidative stress and inflammation; and enhanced the protective factors sirtuin 1, AGE receptor 1 and glyoxalase I. The Reg-AGE diet raised AGEs and markers of insulin resistance, oxidative stress and inflammation. There were no effects on MRI-assessed measurements. No side effects from the intervention were identified. HOMA-IR came down from 3.1 ± 1.8 to 1.9 ± 1.3 (p < 0.001) in the L-AGE group, while it increased from 2.9 ± 1.2 to 3.6 ± 1.7 (p < 0.002) in the Reg-AGE group. CONCLUSIONS/INTERPRETATION: L-AGE ameliorates insulin resistance in obese people with the metabolic syndrome, and may reduce the risk of type 2 diabetes, without necessitating a major reduction in adiposity. Elevated serum AGEs may be used to diagnose and treat 'at-risk' obesity. TRIAL REGISTRATION: ClinicalTrials.gov NCT01363141 FUNDING: The study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (DK091231).


Subject(s)
Glycation End Products, Advanced/therapeutic use , Insulin Resistance/physiology , Obesity/metabolism , 3T3-L1 Cells , Aged , Aged, 80 and over , Animals , Blood Glucose/drug effects , Blotting, Western , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/drug therapy , Female , Humans , Inflammation/blood , Inflammation/drug therapy , Insulin/blood , Insulin Resistance/genetics , Male , Metabolic Syndrome/blood , Metabolic Syndrome/drug therapy , Mice , Middle Aged , Obesity/genetics , Oxidative Stress/drug effects , Oxidative Stress/genetics , Reverse Transcriptase Polymerase Chain Reaction , Risk Factors , Waist Circumference/drug effects , Waist Circumference/genetics
19.
Rev. esp. geriatr. gerontol. (Ed. impr.) ; 50(5): 223-231, sept.-oct. 2015. tab, ilus
Article in Spanish | IBECS | ID: ibc-140492

ABSTRACT

Introducción. En occidente, más del 10% de las personas mayores de 65 años padecen anemia. Hasta en un tercio de los mismos esta es inexplicada. La anemia inexplicada de la persona mayor (AI) se considera un diagnóstico de exclusión, sin que exista un consenso en los criterios para su abordaje clínico o experimental. En estudios en animales y humanos se ha evidenciado que existe un vínculo entre envejecimiento y anemia. Objetivos. Conocer si existe evidencia en la literatura que soporte como causa de AI al agotamiento de células madre hematopoyéticas (CMH) y al acúmulo de productos finales de la glicación avanzada (AGE). Método. Tras una revisión exhaustiva de la literatura se seleccionaron 32 trabajos de investigación (28 para agotamiento de CMH y 4 para AGE). Se vincularon sus conclusiones a los mecanismos y efectos tanto del agotamiento de CMH como del acúmulo de AGE sobre el envejecimiento y la anemia. Resultados. Únicamente 3 trabajos relacionaron la AI con el agotamiento de CMH y 2 de ellos difirieron en sus conclusiones, el tercero difirió en el tipo de estudio. Existe relación del incremento y acúmulo de AGE con anemia en la persona mayor. Conclusión. Existe evidencia en la literatura que vincula los mecanismos moleculares y celulares del envejecimiento con el agotamiento de CMH y el acúmulo de AGE, también existe evidencia de que ambas entidades condicionan anemia relacionada a la edad en animales y humanos. Hay una pobre evidencia en la literatura que determine una relación entre envejecimiento y AI (AU)


Introduction. More than 10% of the aged 65 years and over in the western world suffers anemia and in one third of them the cause of the anemia remains obscure. The unexplained anemia of the elderly (UAE) is considered an exclusion diagnosis, without the existence of a clear consensus to its clinical or experimental approach. There is an association between aging and anemia in studies performed in animals and in humans. Objectives. To determine if there is evidence in the literature that supports hematopoietic stem cells (HSC) exhaustion and the advanced glycation end-products (AGE's) as a cause of UAE. Method. A total of 32 combined texts (28 for HSC exhaustion and 4 for AGEs) were selected after an intensive review. Conclusions were associated with causes and effects of the HSC exhaustion and circulating AGE's over aging and anemia. Results. Only three works try to establish an association between UAE and HSC exhaustion, two of them disagreed in their conclusions, with the third one differing in the type of study. There is a relationship between anemia and AGEs increase and accumulation. Conclusions. There is evidence in the literature that links the aging molecular and cellular mechanisms with the HSC exhaustion and the increase of AGE's. Furthermore; there is some evidence that both conditions determine the emergence of anemia associated with age in animals and in humans. There is little evidence in the literature to clarify the relationship between aging and UAE (AU)


Subject(s)
Aged, 80 and over , Aged , Female , Humans , Male , Glycation End Products, Advanced/physiology , Glycation End Products, Advanced/standards , Glycation End Products, Advanced/therapeutic use , Anemia/complications , Anemia/therapy , Stem Cells/physiology , Hematopoietic Stem Cells/physiology , Hematopoietic Stem Cells , Erythropoiesis/physiology , Hematopoietic Stem Cells , Hematopoietic Cell Growth Factors/isolation & purification , Aging/physiology
20.
Postepy Hig Med Dosw (Online) ; 68: 1264-75, 2014 Nov 07.
Article in Polish | MEDLINE | ID: mdl-25380209

ABSTRACT

In the view of constantly increasing number of reports about participation of advanced oxidation protein products (AOPPs) in pathogenesis of many diseases as well as in the pathomechanism of their biochemical disturbances and clinical complications, the possibility of treatment of these diseases by reducing of AOPPs concentration and prevention or inhibition of their formation poses the object of intensive investigations. The first investigated agents, with proven efficacy in prevention of AOPPs formation, was N-acetylcysteine. In relationship with the fact, that the intensified formation of AOPPs is closely connected with intensity of oxidative stress (OS), so the possibility of use of agents and/or drugs with well-known antioxidative proprieties, also natural origin, was examined. It is very important in aspects of its self-treatment by patients. The next step was the estimation of possibility of utilization of pleiotropic properties of drugs routinely applied in the treatment of civilization diseases, especially hypertension and diabetes, often with kidneys insufficiency. On the basis of known mechanism of the unfavorable acting of AOPPs (induction of intracellular signal transduction, and secondary intensyfication of OS), on the way of its connection with the RAGE receptor [similarly as advanced glycation end products (AGEs)], indicated on the possibility of new therapeutic strategies, through the blocking of RAGE-AGEs interactions or using the soluble form of this receptor. Discussed in this paper results of investigations shows the possibility to introduction in the near future, the innovative therapeutic strategies, directed just on the AOPPs, permitting on the limitation of their formation and accumulation in tissues and organs, especially in kidneys. This will permit for the break of mechanism of vicious circle of interaction OS and oxidatively modified macromolecules and attenuating of biochemical and clinical disturbances in the diseases connected with AOPPs participating.


Subject(s)
Advanced Oxidation Protein Products/metabolism , Advanced Oxidation Protein Products/therapeutic use , Antioxidants/therapeutic use , Diabetes Mellitus/drug therapy , Glycation End Products, Advanced/metabolism , Glycation End Products, Advanced/therapeutic use , Hypertension/drug therapy , Antioxidants/metabolism , Diabetes Mellitus/metabolism , Humans , Hypertension/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...